Skip to main content
. 2019 Mar 6;2019(3):CD012930. doi: 10.1002/14651858.CD012930.pub2

1. Characteristics of included studies.

Study RCT Design N rand. Country/region Interventiona (dose in μg) Participant baseline characteristics
Age, yearsb Male (%)b % pred. FEV1c Smoking status ICS use (%)b,d
Bateman 2013 Parallel 709 Worldwide IND/GLY 110/50 64.0‐64.4 73‐76 55 40.1‐40.5 56.5‐57.8
Beeh 2014 Cross‐over 85 NS IND/GLY 110/50 62.1 63 47 45 31
Beeh 2015 Cross‐over 219 Europe, N. America TIO/OLO 2.5/5; 5/5 61.1 59 54 62.6 41.1
Celli 2014 Parallel 678 NS UMEC/VI 125/25 62.2‐63.4 64‐66 48 50‐52 44‐50
Dahl 2013 Parallel 339 Europe, Canada, Asia and South Africa IND/GLY 110/50 62.5‐62.9 76‐77 57.5 45.1‐45.3 38.9‐45.8
Donohue 2013 Parallel 693 Worldwide UMEC/VI 62.5/25 62.2‐63.1 70‐74 47.5 49‐54 49‐51
Feldman 2012 Parallel 51 USA UMEC/VI 500/25 58.7‐59.2 57‐78 50 57‐78 NR
Larbig 2015 Parallel 811 Worldwide IND/GLY 110/50 64.6‐64.9 71‐77 NR NR NR
Mahler 2014 Cross‐over 247 Europe, N. America IND/GLY 110/50 62.8 70 56 45.5 54.9
Maltais 2014 Parallel 404 Europe, N. America, S. America TIO/OLO 2.5/5; 5/5 60.8‐63.1 65‐68 59 NR NR
Maltais 2014b Cross‐over 349 Europe, N. America, S. Africa UMEC/VI 62.5/25; 125/25 61.6 56 51 63.2 28.2
Maltais 2014c Cross‐over 308 Europe, N. America, Russia UMEC/VI 62.5/25; 125/25 62.6 55 51 60.6 39.4
NCT00626522 Parallel 425 Europe, Australia, Russia ACD/FOR 200/6; 200/12; 200/18 60.7‐63.9 75‐82 NR NR NR
NCT02275052 Cross‐over 99 USA UMEC/VI 62.5/25 60.7 53 NR NR NR
O'Donnell 2015a Cross‐over 586 N. America, S. America, Oceania, Europe TIO/OLO 2.5/5; 5/5 61.7 71 58 39.1 NR
O'Donnell 2015b Cross‐over   N, America, S. America, Russia, Europe TIO/OLO 2.5/5; 5/5 61.7 71 58 39.1 NR
Siler 2016 Parallel 498 Europe, USA, Russia UMEC/VI 62.5/25 62.6‐64.1 58‐60 47.5 52‐55 45‐50
Singh 2016a Parallel 608 Europe, N. America, S. Africa TIO/OLO 2.5/5; 5/5 64.7‐65.1 56‐62 55.5 43.1‐54.7 34.8‐41.9
Singh 2016b Parallel 606 Europe N. America, S. Africa, Oceania TIO/OLO 2.5/5; 5/5 64.0‐65.2 58‐66 54.5 44.6‐47.0 35.1‐41.1
Troosters 2016 Parallel 152 Europe, Canada, Oceania TIO/OLO 5/5 64.4‐65.0 63‐69 NR NR NR
Watz 2016 Cross‐over 194 Germany IND/GLY 110/50 62.8 66 62 56.7 NR
Zheng 2014 Parallel 580 China, South‐east Asia UMEC/VI 62.5/25; 125/5 63.7‐64.3 92‐94 NR 25‐34 51‐54

aPlacebo was the comparator in all studies.
 bRange across treatment arms reported where overall data were not reported.
 c % predicted FEV1 post‐bronchodilator.
 dConcomitant ICS use was permitted in all studies (not stated for Celli 2014, Larbig 2015; NCT00626522; Troosters 2016).

Abbreviations: ACD: aclidinium; FOR: formoterol; GLY: glycopyrronium; IND: indacaterol; NR: not reported; OLO: olodaterol; rand: randomised; RCT: randomised controlled trial; TIO: tiotropium; UMEC: umeclidinium; VI: vilanterol.